NCT03094156 - Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2006

Primary Completion Date

July 11, 2006

Study Completion Date

July 11, 2006

Conditions

Parkinson Disease

Interventions

DRUG

Placebo

1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]

DRUG

BIA 6-512

1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]

DRUG

Madopar® 250

Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]

DRUG

Comtan®

Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]

Trial Locations (1)

4745-457

Human Pharmacology Unit (UFH) - BIAL - Portela & Cª, SA, S. Mamede Do Coronado

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY